The firm reports an accumulated deficit of approximately $154.8 million, reflecting significant long-term value erosion despite the absence of long-term debt.
| Metric | TTM | Jun'25 | Jun'24 | Jun'23 | Jun'22 | Jun'21 | Jun'20 | Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 | Jun'09 | Jun'08 | Jun'07 | Jun'06 | Jun'05 |
|---|
| Total Current Assets | 3.38T | 1.67M | 4.97M | 8.45M | 14.42M | 20.82M | 13.99M | 2.83M | 7.32M | 15.29M | 24.38M | 31.68M | 37.66M | 14.52M | 14.59M | 9.56M | 7.46M | 2.12M | 1.25M | 1.22M | 2.72M | 0 |
| Cash & Short-Term Investments | 3.21T | 1.56M | 4.8M | 8.15M | 14.07M | 20.52M | 13.71M | 2.56M | 7.08M | 15.1M | 24.16M | 31.47M | 36.7M | 13.92M | 14.27M | 9.22M | 6.96M | 1.69M | 816.39K | 967.8K | 2.51M | 0 |
| Cash Only | 3.21T | 1.56M | 4.8M | 8.15M | 14.07M | 20.52M | 13.71M | 2.56M | 7.08M | 15.1M | 24.16M | 31.47M | 36.7M | 13.92M | 14.27M | 9.22M | 6.96M | 1.69M | 816.39K | 967.8K | 2.51M | 0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 164.66B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 150K | 0 | 0 | 0 | 209.9K | 109.31K | 102.87K | 20K | 0 | 0 |
| Total Non-Current Assets | 6.84T | 7.15M | 7.85M | 8.45M | 9.08M | 9.44M | 9.93M | 10.62M | 11.22M | 11.71M | 12.25M | 12.5M | 6.91M | 1.89M | 1.04M | 1.2M | 1.54M | 880.96K | 220.45K | 125.7K | 8.77K | 0 |
| Property, Plant & Equipment | 6.53T | 6.83M | 7.51M | 8.11M | 8.69M | 9.08M | 9.54M | 10.23M | 10.84M | 11.27M | 11.76M | 11.96M | 5.5M | 468.9K | 614.84K | 802.37K | 1.17M | 688.62K | 133.74K | 18.49K | 2.05K | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 310.84B | 317.04K | 325.31K | 333.58K | 341.85K | 350.12K | 358.39K | 366.66K | 374.93K | 383.2K | 391.47K | 399.74K | 408.26K | 417.03K | 425.81K | 0 | 367.08K | 192.34K | 6.71K | 7.21K | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.52K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.38B | 2.44K | 14.56K | 14.36K | 42.44K | 3.52K | 25.86K | 29.19K | 8.16K | 58.93K | 99.54K | 142.53K | 1M | 1M | 0 | 0 | 0 | 0 | 80K | 100K | 6.71K | 0 |
| Total Assets | 10.22T | 8.82M | 12.82M | 16.9M | 23.49M | 30.26M | 23.91M | 13.45M | 18.55M | 27M | 36.63M | 44.19M | 44.57M | 16.41M | 15.63M | 10.76M | 8.99M | 3M | 1.47M | 1.35M | 2.73M | 0 |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 199999740% | -31.18% | -24.12% | -28.07% | -22.36% | 26.54% | 77.82% | -27.49% | -31.32% | -26.29% | -17.09% | -0.86% | 171.64% | 4.98% | 45.28% | 19.64% | 199.62% | 104.41% | 8.74% | -50.53% | - | - |
| Total Current Liabilities | 1.07T | 1.31M | 1.36M | 534.25K | 412.84K | 351.15K | 2.16M | 2.85M | 881.95K | 4.67M | 6.74M | 600.89K | 1.23M | 1.18M | 1.78M | 587.18K | 2.47M | 515.72K | 1.02M | 849.88K | 574.06K | 66K |
| Accounts Payable | 1.04M | 1.28M | 376.27K | 157.06K | 57.96K | 200.02K | 380.73K | 309.89K | 223.34K | 135.79K | 96.52K | 89.52K | 376.45K | 263.26K | 238.36K | 542.48K | 1.32M | 448.04K | 669.95K | 334.88K | 247.12K | 48.48K |
| Days Payables Outstanding | 153.68M | - | - | - | - | - | - | 162.54 | 119.87 | 74.76 | 53.42 | - | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 94.79K | 95.31K | 1.14M | 0 | 0 | 3.96M | 5.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 541.37K | 969.72K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.07T | 0 | 958.97K | 338.13K | 214.4K | 0 | 592.58K | 2.53M | 638.89K | 539.58K | 1.14M | 482.86K | 49.45K | 0 | 1.08M | 17.52K | 1.13M | 0 | 0 | 0 | 90.83K | 0 |
| Current Ratio | 3.17x | 1.28x | 3.66x | 15.81x | 34.92x | 59.30x | 6.49x | 0.99x | 8.30x | 3.28x | 3.62x | 52.72x | 30.70x | 12.33x | 8.20x | 16.28x | 3.01x | 4.11x | 1.22x | 1.44x | 4.74x | - |
| Quick Ratio | 3.17x | 1.28x | 3.66x | 15.81x | 34.92x | 59.30x | 6.49x | 0.99x | 8.30x | 3.28x | 3.62x | 52.72x | 30.70x | 12.33x | 8.20x | 16.28x | 3.01x | 4.11x | 1.22x | 1.44x | 4.74x | - |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 1.5M | 0 | 0 | 0 | 0 | 0 | 2.02M | 6.84M | 11.8M | 14.74M | 7.22M | 0 | 0 | 0 | 0 | 0 | 0 | 917.08K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.13M | 7.18M | 9.04M | 3.47M | 0 | 0 | 0 | 0 | 0 | 0 | 917.08K | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 1.5M | 0 | 0 | 0 | 0 | 0 | 2.02M | 3.71M | 4.62M | 5.7M | 3.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.07T | 1.31M | 1.36M | 2.03M | 412.84K | 351.15K | 2.16M | 2.85M | 881.95K | 6.68M | 13.59M | 12.4M | 15.96M | 8.4M | 1.78M | 587.18K | 2.47M | 515.72K | 1.02M | 849.88K | 1.49M | 66K |
| Total Debt | 0 | 0 | 0 | 0 | 94.79K | 95.31K | 1.14M | 0 | 0 | 3.96M | 8.61M | 7.18M | 9.04M | 3.47M | 0 | 0 | 0 | 0 | 0 | 0 | 917.08K | 0 |
| Net Debt | -3.21T | -1.56M | -4.8M | -8.15M | -13.97M | -20.42M | -12.56M | -2.56M | -7.08M | -11.14M | -15.55M | -24.29M | -27.66M | -10.46M | -14.27M | -9.22M | -6.96M | -1.69M | -816.39K | -967.8K | -1.59M | 0 |
| Debt / Equity | 0.00x | - | - | - | 0.00x | 0.00x | 0.05x | - | - | 0.19x | 0.37x | 0.23x | 0.32x | 0.43x | - | - | - | - | - | - | 0.74x | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 421741.49x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -165.52x | -9155.26x | -1581.44x | -102.38x | -85.37x | - | -17.03x | -4.51x | -3.59x | -1.85x | -2.37x | -7.13x | - | - | - | - | - | -33.44x | - | - |
| Total Equity | 9.15T | 7.52M | 11.46M | 14.87M | 23.08M | 29.91M | 21.76M | 10.6M | 17.66M | 20.32M | 23.05M | 31.79M | 28.6M | 8.01M | 13.85M | 10.17M | 6.52M | 2.49M | 443.74K | 500.34K | 1.24M | -66K |
| Equity Growth % | 199999736.56% | -34.42% | -22.88% | -35.6% | -22.83% | 37.47% | 105.26% | -39.99% | -13.08% | -11.83% | -27.49% | 11.12% | 257.13% | -42.17% | 36.17% | 56.03% | 162.26% | 460.14% | -11.31% | -59.6% | 1976.31% | - |
| Book Value per Share | 423601.14 | 0.50 | 0.97 | 1.28 | 2.00 | 2.74 | 3.87 | 2.95 | 5.44 | 6.76 | 7.99 | 10.73 | 11.17 | 3.36 | 6.48 | 5.12 | 3.50 | 1.45 | 0.27 | 0.31 | 0.84 | -0.05 |
| Total Shareholders' Equity | 9.15T | 7.52M | 11.46M | 14.87M | 23.08M | 29.91M | 21.76M | 10.6M | 17.66M | 20.32M | 23.05M | 31.79M | 28.6M | 8.01M | 13.85M | 10.17M | 6.52M | 2.49M | 443.74K | 500.34K | 1.24M | -66K |
| Common Stock | 216M | 166 | 131 | 116 | 116 | 11.52K | 9.08K | 76.9K | 69.17K | 63.3K | 58.18K | 57.24K | 54.62K | 47.03K | 155.65K | 143.58K | 133.98K | 125.3K | 119.27K | 114.07K | 108.88K | 100K |
| Retained Earnings | -154.84T | -148.84M | -139.37M | -131.08M | -122.49M | -114.39M | -105.56M | -92.12M | -83.69M | -75.13M | -64.82M | -54.1M | -52.41M | -38.3M | -29.42M | -23.22M | -16.74M | -12M | -9.21M | -6.47M | -3.35M | -165.99K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20 | -20 | -20 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity exhaustion
As reported in recent financial statements, NanoViricides' cash position has dwindled to approximately $1.56 million, a level that appears insufficient to sustain the company's ongoing clinical research operations without immediate external capital infusion or a significant reduction in the current quarterly cash burn rate.
The current ratio has fluctuated significantly, reflecting the company's reliance on periodic equity financing to maintain its liquidity buffer. Investors should monitor the potential for further dilution, as the current cash runway appears inadequate to support the firm's R&D-heavy business model through the next phase of clinical development.
Based on the provided balance sheet data, the company's asset composition is heavily weighted toward intangible assets and specialized property, plant, and equipment, which together represent the vast majority of the firm's total reported assets as of the most recent quarterly filing.
The concentration of value in non-liquid assets suggests that the company's fundamental worth is tied entirely to the success of its proprietary platform rather than tangible collateral. This asset structure leaves little room for balance sheet flexibility should the company need to pivot its strategy or secure debt-based financing.
According to historical balance sheet figures, the company's equity base has been consistently eroded by accumulated deficits, which have reached approximately $154.8 million as of the latest reporting period, signaling a long-term trend of value destruction for shareholders in the absence of commercial revenue.
The persistent negative retained earnings highlight the high cost of maintaining a clinical-stage biotech operation without a successful product launch. This trend suggests that the company's equity value is highly sensitive to the market's perception of its future clinical milestones rather than its current book value.
As evidenced by the company's financial disclosures, the absence of long-term debt masks the underlying risk of operational insolvency, as the firm's reliance on equity markets for survival creates a structural vulnerability that is not fully captured by traditional leverage metrics like debt-to-equity ratios.
While the lack of debt may appear favorable, it reflects a business model that is entirely dependent on the continuous issuance of new shares to fund operations. This reliance on equity markets warrants further investigation into the potential for future share dilution, which could significantly impact the value of existing holdings.
Quick answers to the most common questions about buying NNVC stock.
As of 2025, NanoViricides, Inc. (NNVC) had total assets of $8.8M including $1.7M in current assets.
NanoViricides, Inc. (NNVC) carries total debt of $0.0M, offset by $1.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
NanoViricides, Inc. (NNVC) has total shareholders' equity (book value) of $7.5M ($0.50 book value per share). Book value represents the net worth of the company belonging to common stock holders.
NanoViricides, Inc. (NNVC) reported a current ratio of 1.28x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.